Safety of 5914 intravitreal ziv-aflibercept injections

Simple item page
dc.contributor.authorBraimah, I.Z.
dc.contributor.authorSingh, S.R.
dc.contributor.authorStewart, M.W.
dc.contributor.authorChattannavar, G.
dc.contributor.authorAshraf, M.
dc.contributor.authorSouka, A.
dc.contributor.authorElDardeery, M.
dc.contributor.authorWadhwa, N.
dc.contributor.authorSarvaiya, C.
dc.contributor.authorMansour, A.M.
dc.contributor.authorMarashi, A.
dc.contributor.authorRamchandani, S.
dc.contributor.authorBonyadi, M.H.J.
dc.contributor.authorRamezani, A.
dc.contributor.authorSoheilian, M.
dc.contributor.authorde Oliveira Dias, J.
dc.contributor.authorde Andrade, G.C.
dc.contributor.authorMaia, A.
dc.contributor.authorRodrigues, E.B.
dc.contributor.authorFarah, M.E.
dc.contributor.authorBanker, A.
dc.contributor.authorChhablani, J.
dc.date.accessioned2019-09-16T12:53:56Z
dc.date.available2019-09-16T12:53:56Z
dc.date.issued2018-07-02
dc.descriptionResearch Articleen_US
dc.description.abstractPurpose To analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions. Methods This was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated. Patient demographics and ocular details were compiled. Ocular and systemic adverse events that occurred within 1 month of IVZ injections were recorded and defined as either procedure-related or drug-related. Results A total of 1704 eyes of 1562 patients received 5914 IVZ injections (mean±SD: 3.73±3.94) during a period of 2.5 years. The age of patients was 60.6±12.8 years (mean±SD) and included diverse chorioretinal pathologies. Both ocular (one case of endophthalmitis, three cases of intraocular inflammation, and one case each of conjunctival thinning/necrosis and scleral nodule) and systemic adverse events (two cases of myocardial infarction, one case of stroke and two deaths) were infrequent. Conclusion This constitutes the largest pooled safety report on IVZ use and includes patients from 14 centres distributed across the globe. It shows that IVZ has an acceptable ocular and systemic safety profile with incidences of adverse events similar to those of other vascular endothelial growth factor inhibitory drugs. The analysis supports the continued use of IVZ in various retinal disorders.en_US
dc.identifier.citationSingh SR, Stewart MW, Chattannavar G on behalf of the Ziv-aflibercept Study Group, et alSafety of 5914 intravitreal ziv-aflibercept injectionsBritish Journal of Ophthalmology 2019;103:805-810.en_US
dc.identifier.otherhttp://dx.doi.org/10.1136/bjophthalmol-2018-312453
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/32201
dc.language.isoenen_US
dc.publisherBritish Journal of Ophthalmologyen_US
dc.relation.ispartofseries103;6
dc.subjectintravitrealen_US
dc.subjectziv-aflibercept injectionsen_US
dc.subjectSafetyen_US
dc.titleSafety of 5914 intravitreal ziv-aflibercept injectionsen_US
dc.typeArticleen_US

Files

License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Department of Surgery